Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects
1-3% of the adults and up to 25% of the children in the United States. Patients with severe
AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form)
to evaluate the immune suppression and pathological correlation of cyclosporine A in these
patients in order to determine the extent to which immune activation drives the pathological
epidermal phenotype.